Publication details

Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories.

Authors

FIEGL M. ERDEL M. TINHOFER I. BRYCHTOVÁ Yvona PANOVSKÁ Anna DOUBEK Michael EIGENBERGER K. FONATSCH C. HOPFINGER G. MÜHLBERGER H. ZABERNIGG A. FALKNER F. GASTL G. MAYER Jiří GREIL R.

Year of publication 2010
Type Article in Periodical
Magazine / Source Annals of Oncology
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1093/annonc/mdq236
Field Oncology and hematology
Keywords alemtuzumab; chronic lymphocytic leukemia; cytogenetic abnormalities; FISH
Description Patients and methods: Data were collected from 105 consecutive, pretreated, cytogenetically defined patients who had received alemtuzumab. Response, progression-free survival (PFS), and overall survival (OS) were assessed. Results: The hierarchic incidence of cytogenetic abnormalities was: 13q deletion (as sole abnormality), 18%; trisomy 12, 13%; 11q deletion, 19%; 17p deletion, 33%; and none of these, 16%. Overall response rate (ORR) was 43% in the total cohort and 49% in the subgroup of 17p-deleted patients (n = 35). From the start of alemtuzumab monotherapy, median PFS in the total cohort and in the subgroup of 17p-deleted patients was 7.0 and 7.1 months, respectively. Median OS in the total cohort and in 17p-deleted patients was 32.8 and 19.1 months, respectively. The poor-risk group of patients with CLL (i.e. fludarabine resistant, 17p deletion; n = 20) showed encouraging ORR, PFS, and OS (35%, 7.0 and 19.2 months, respectively). Conclusions: Alemtuzumab was effective in treating patients with CLL across the cytogenetic categories evaluated, but there were differences. In patients with CLL with 17p deletion quite favorable ORR, PFS, and OS were achieved.

You are running an old browser version. We recommend updating your browser to its latest version.

More info